Roivant President and Immunovant CEO Eric Venker disposes of 200,000 common shares worth $7,324,000

• Roivant Sciences President and Immunovant CEO Eric Venker sold 200,000 common shares at a weighted-average price of $36.62.
• Sale cut his direct stake to 1,599,154 common shares.
• He also exercised stock options for 200,000 shares at $3.85.
• Transaction date was Sept. 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001635088-26-000108), on October 02, 2026, and is solely responsible for the information contained therein.